ultrasound for liver disease

Liver Analysis Solution

Liver Analysis Solution

Advanced liver analysis solution to
comprehensive liver
assessment and clarification needed

Quick statistics on liver disease

Global statistics of liver cancer

Cancer is a leading cause of death worldwide, accounting for about 10 million deaths in the year 2020 [1]. Liver cancer is a global burden, the 6th most common cancer, and about 900,000 people are diagnosed each year [2]. Moreover, according to the WHO, liver cancer is marked 3rd most common cause of cancer death in 2020 (830,000 deaths) [1].

liver cancer statistics

The most common causes of cancer deaths in 2020 [1]

1 in 4 of global population have NAFLD

NAFLD statistics

Non-Alcoholic Fatty Liver Disease (NAFLD) is an umbrella term that encompasses a spectrum of disorders, such as fat deposits in the liver, steatohepatitis, liver fibrosis, and cirrhosis, which can be found during an ultrasound and liver biopsy and are neither caused by alcohol consumption nor accompanied by other disorders.

Recent figures show that the prevalence of NAFLD in Asia and the USA is approximately 30%, while its global prevalence is approximately 25% [4].

Fat deposits in the liver can increase the chances of triggering inflammatory responses and also lead to liver fibrosis. Hence, it is important to continuously monitor the liver once the patient is diagnosed with fatty liver disease.

Liver Analysis Solution

Our liver analysis solution is available to track from the beginning to Post-op follow ups, covering wide range of liver disease.

liver diagnosis Solutions
liver diagnosis Solutions

Fatty Liver

Hepato-renal index (bright comparison)
with automated ROI recommendation

EzHRI™ places 2 ROIs on the liver parenchyma and renal cortex and provides HRI* ratio. It offers convenience and an improved workflow by suggesting initial ROIs, calculates the average brightness ratio of the liver parenchyma and the renal cortex.

EzHRI™ : Normal liver ultrasound images
EzHRI™ : ultrasound images of fatty liver
HRI : Hepato-Renal Index
The Hepatorenal Index, the brightness ratio of the liver parenchyma over the renal cortex is used to classify abnormal fatty liver.

Quantitative tissue attenuation measurement
to assess steatotic liver changes

TAI™ (Tissue Attenuation Imaging) is a tool that quantitatively measures the attenuation of ultrasound signals received from the liver. TAI™ quantifies attenuation based on changes in the center frequency under the optimal transmission and reception conditions.

TAI™ : normal liver on ultrasound
TAI™ : fatty liver images ultrasound

Quantitative tissue scatter distribution
measurement to assess steatotic liver changes

TSI™ (Tissue Scatter Distribution Imaging) is a tool that quantifies the scattered signal distribution based on backscattered signals. Scattering, the reflection of ultrasound waves in multiple directions not affected by their entry angle, produces speckle patterns in ultrasound images and this changes the distribution of backscattered ultrasound signals based on the scattering intensity.

TSI™ : Normal liver ultra sound image
TSI™ : fatty liver ultrasound image

Liver Fibrosis

Provide non-invasive assessment of the tissue
stiffness in patient with cirrhotic and fibrous livers

S-Shearwave Imaging™ allows for non-invasive assessment of the stiffness of tissue/lesions liver. The color-coded elastogram, quantitative measurements, dual or single display option, and user-selectable ROI functions are especially useful for the accurate diagnosis liver diseases.

 S-Shearwave Imaging™ : liver diagnosis Solutions
 S-Shearwave Imaging™ : liver diagnosis Solutions


Contrast Enhanced Ultrasound

CEUS+ is a contrast enhancement imaging technology that utilizes the characteristics of ultrasound contrast agents. The microbubble contrast agent injected into the body through the vein or alike is subjected to perform nonlinear resonance due to stimulation of ultrasound energy. In addition to the nonlinear signal generated by this method, the ultrasound contrast image is implemented by using the harmonic signal and thus utilized for the diagnosis based on the contrast characteristics over time.

CEUS+: contrast enhanced ultrasound

Visualize slow flow in microvascular structures

MV-Flow™ visualizes microcirculatory and slow blood flow to display the intensity in color. It is suitable for observation of microcirculatory and volume of slow blood flow.

MV-Flow™ : Color imaging
MV-Flow™ : Color imaging


Perform multi-modality fusion biopsies with high precision

S-Fusion™ for liver enables simultaneous localization of a lesion using real-time ultrasound in conjunction with other volumetric imaging modalities. Samsung's auto registration helps quickly and precisely fuse the images, increasing efficiency and reducing procedure time. S-Fusion™ enables precise targeting during interventional and other advanced clinical procedures.

S-Fusion™ : Performing fusion ultrasound fusion biopsies
S-Fusion Registration having fusion ultrasound biopsy methods

Matching Auto allows automatic initial registration by attaching external markers to the patient’s body before S-Fusion™ exam is processed, thus it helps quick and accurate exam.

Matching Auto using external marker for automatic initial registration

Positioning Auto helps quick and efficient examination with one-step initial registration between CT/MR and ultrasound images by positioning the transducer in the patient’s pit of the stomach before patient scan.

Positioning Auto using external marker for initial registration between CT/MR and ultrasound liver images

Tool to provide needle path and target mark during
interventional procedures

S-Tracking increases accuracy during interventional procedures by providing a simulated needle path and target mark within the live ultrasound image. Clear Track, one of two functions provided by S-Tracking, ensures accuracy by using a specialized needle with a sensor tip. S-Tracking also includes Virtual Track utilizing conventional needles to provide both accuracy and economic benefit.

S Tracking for ultrasound needle guide
S-Tracking for interventional procedures

Clinical Videos

New Guidelines for Liver Stiffness Quantification

New guidelines for Liver Stiffness Quantification
  • Richard G. Barr MD, PhD, FACR, FSRU, FAIUM
    Professor of Radiology
    Northeastern Ohio Medical University
  • 55:23

Supported Systems

Related Papers

Tech Leaflet

  • Leaflet about fatty liver ultrasound
    Learn More

White Paper

  • CEUS+: contrast enhanced ultrasound white paper
    Learn More
  • S-Shearwave Imaging™ white paper
    Learn More


  • World Health Organization, 2022, Cancer, https://www.who.int/news-room/fact-sheets/detail/cancer
  • World Health Organization-The Global Cancer Observatory, 2020, Liver, https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf
  • Naga Chalasani, et al., The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology, 2018, 67.1, 328-357.
  • Cha DI, Kang TW, Min JH, Joo I, Sinn DH, Ha SY, et al. Deep learning-based automated quantification of the hepatorenal index for evaluation of fatty liver by ultrasonography. Ultrasonography 2021 Feb 24 [Epub]. https://doi.org/10.14366/usg.20179
  • Jeon SK, Joo I, Kim SY, Jang JK, Park J, Park HS, et al. Quantitative ultrasound radiofrequency data analysis for the assessment of hepatic steatosis using the controlled attenuation parameter as a reference standard. Ultrasonography 2020 May 9 [Epub]. https://doi.org/10.14366/usg.20042
  • Jeon SK, Lee JM, Joo I, Park SJ. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard. Korean J Radiol. 2021 Jul;22(7):1077-1086.https://doi.org/10.3348/kjr.2020.1262


  • Some features listed on this webpage may be options that require purchase.
  • The above is a description of liver analysis solution - related overall functions, and these functions may not be available in all products.
  • This product, features, options, and transducers are not commercially available in all countries.
  • Sales and Shipments are effective only after the approval by the regulatory affairs.
  • Please contact your local sales representative for further details.
  • This product is a medical device, please read the user manual carefully before use.